380 related articles for article (PubMed ID: 10340907)
21. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
Schuettfort VM; Pradere B; D'Andrea D; Grossmann NC; Quhal F; Mostafaei H; Laukhtina E; Mori K; Rink M; Karakiewicz PI; Motlagh RS; Katayama S; Lotan Y; Scherr D; Abufaraj M; Fajkovica H; Compérat E; Enikeev D; Shariat SF
J Urol; 2021 Nov; 206(5):1122-1131. PubMed ID: 34181469
[TBL] [Abstract][Full Text] [Related]
22. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.
Schneider UV; Nielsen RL; Pedersen C; Eugen-Olsen J
BMC Infect Dis; 2007 Nov; 7():134. PubMed ID: 18021410
[TBL] [Abstract][Full Text] [Related]
24. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
[TBL] [Abstract][Full Text] [Related]
25. Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Schmidt M; Hoppe F
Acta Otolaryngol; 1999; 119(8):949-53. PubMed ID: 10728940
[TBL] [Abstract][Full Text] [Related]
26. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.
Lawn SD; Myer L; Bangani N; Vogt M; Wood R
BMC Infect Dis; 2007 May; 7():41. PubMed ID: 17509133
[TBL] [Abstract][Full Text] [Related]
27. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
28. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
[TBL] [Abstract][Full Text] [Related]
29. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
30. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
[TBL] [Abstract][Full Text] [Related]
31. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
32. Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Usnarska-Zubkiewicz L; Strutyńska-Karpińska M; Zubkiewicz-Kucharska A; Zarębski P; Grabowski K
Adv Clin Exp Med; 2014; 23(6):959-67. PubMed ID: 25618124
[TBL] [Abstract][Full Text] [Related]
33. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
McCabe NP; Angwafo FF; Zaher A; Selman SH; Kouinche A; Jankun J
Oncol Rep; 2000; 7(4):879-82. PubMed ID: 10854562
[TBL] [Abstract][Full Text] [Related]
34. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
Wach S; Al-Janabi O; Weigelt K; Fischer K; Greither T; Marcou M; Theil G; Nolte E; Holzhausen HJ; Stöhr R; Huppert V; Hartmann A; Fornara P; Wullich B; Taubert H
Int J Cancer; 2015 Sep; 137(6):1406-16. PubMed ID: 25754273
[TBL] [Abstract][Full Text] [Related]
35. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Järvinen H; Roberts P
Eur J Cancer; 1996 Jun; 32A(7):1156-61. PubMed ID: 8758246
[TBL] [Abstract][Full Text] [Related]
36. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.
Kos J; Nielsen HJ; Krasovec M; Christensen IJ; Cimerman N; Stephens RW; Brünner N
Clin Cancer Res; 1998 Jun; 4(6):1511-6. PubMed ID: 9626470
[TBL] [Abstract][Full Text] [Related]
37. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
[TBL] [Abstract][Full Text] [Related]
38. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer.
Louhimo J; Carpelan-Holmström M; Alfthan H; Stenman UH; Järvinen HJ; Haglund C
Int J Cancer; 2002 Oct; 101(6):545-8. PubMed ID: 12237895
[TBL] [Abstract][Full Text] [Related]
39. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
40. [Predictive value of combination detection of tissue Pgp1 expression and preoperative serum CEA level for colorectal cancer].
Wu F; Chen L; Wu W; Jiang B; Su X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):443-449. PubMed ID: 28440527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
